drugset
drugset / Trial / NCT03161418

Study of the Safety of KSP Heptapeptide (KSP-910638G)

NCT03161418 ↗

Phase 1 Completed 26 enrolled University of Michigan
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the safety of orally administered KSP-910638G, a topically administered li-cor IRDye800CW labeled heptapeptide specific for human epithelial growth factor receptor 2 (HER2).

Timeline

Start
2017-06-21
Primary completion
2017-09-20
Completion
2017-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject KSP-910638G Unknown 0.4 mg Oral
Subject KSP-910638G Unknown 1.2 mg Oral

Indications

No indication recorded.